Hilfe
Produkte
Kontakt
+ Exposé schalten
Yasni Login
DE

Md im Yasni Exposé von Christoph Röllig

Exposé-Ansicht
Nachricht senden
Das Exposé gehört mir!
Besucher
(1868 seit 12.02.2010)

Person-Info

301

Christoph Röllig, Facharzt für Innere Medizin @ Universitätsklinikum Dresden, MK1, Dresden

Land: Deutschland, Sprache: Deutsch
Anonym

93 Informationen zu Christoph Röllig

Comparison Between Two Dose Levels of Daunorubicin ...

Principal Investigator: Matthias Hänel, MD. PD Dr. Christoph Röllig, Recruiting. Dresden, Germany. Principal Investigator: Christoph Röllig, MD ...
1x
clinicaltrials.gov 07.01.15  +  

First Top-flight Evidence of TKI Benefit in AML - Medscape

... a tyrosine kinase inhibitor in this type of leukemia, said lead study author Christoph Röllig, MD, from University Hospital Dresden in Germany.
2x
medscape.com 07.01.15  +  

Ungültige URL: Best of ASH Presentations: Platelets, Lenalidomide for MDS ...

... multi-collaborative trial—the SORAML Trial (NCT00893373)—conducted in Germany, presented by Christoph Röllig, MD, from Universitätsklinikum Dresden, ...
2x
ajmc.com 07.01.15  +  

Christoph Röllig, MD | OncoTherapy Network

In this video from the 2014 ASH Annual Meeting, Dr. Röllig discusses the results of the SORAML trial that tested sorafenib in patients with acute ...
2x
oncotherapynetwork.com 07.01.15  +  

Ungültige URL: Novel Combinations of New and Existing Therapies Yield ...

... a tyrosine kinase inhibitor in this type of leukemia,” said lead study author Christoph Röllig, MD, of University Hospital Dresden in Germany.
2x
hematology.org 07.01.15  +  

Prolonged Survival with Sorafenib Plus Standard Chemo in ...

“At this point, there is no clear benefit in overall survival,” Christoph Röllig, MD, from Universitätsklinikum Dresden in Dresden, Germany, said ...
1x
cancertherapyadvisor.com 07.01.15  +  

Ungültige URL: Richard M Stone MD on the SAL-Soraml Trial - newsreels

... Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial," presented by Christoph Röllig, MD.
2x
video.ascopost.com 07.01.15  +  

Presentation - WMDA

Christoph Röllig. Kristina Hölig. Gerhard Ehninger. CLINICAL STUDY PROTOCOL. PLERIXAFOR AS A SALVAGE REGIMEN TO MOBILIZE.
2x
wmda.info 07.01.15  +  

Novel combinations yield promising results for leukemia ...

... a tyrosine kinase inhibitor in this type of leukemia," said lead study author Christoph Röllig, MD, of University Hospital Dresden in Germany.
1x
sciencedaily.com 07.01.15  +  

Old Drug Might Have New Role in AML Tx | Medpage Today

Study Author: Christoph Röllig, MD ... survival in newly diagnosed AML patients compared with placebo, according to Christoph Röllig, MD, ...
2x
medpagetoday.com 07.01.15  +  

Ungültige URL: Tyrosine Kinase Inhibitor Shows Promise in AML - OncLive

Dr. Christoph Röllig. Christoph Röllig, MD. Treatment with the TKI sorafenib in combination with standard chemotherapy increased event-free ...
1x
onclive.com 07.01.15  +  

Richard M. Stone, MD, on the SAL-Soraml Trial on Vimeo

... Leukemia: Results From 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial,” presented by Christoph Röllig, MD.
0x
vimeo.com 07.01.15  +  

Jetzt bewerten

(1)
 1 Bewertung 
5 Sterne (1)
4 Sterne (0)
3 Sterne (0)
2 Sterne (0)
1 Stern (0)

Ihre Verbindung zu Christoph Röllig

Ich
Ich
Christoph Röllig @ Universitätsklinikum Dresden, MK1, Dresden
Christoph

Sie haben noch kein Exposé bei Yasni.

Kontakte von Christoph (0)

Keine Einträge.
Wichtige Personen: Heute - Übersicht / Namen: Heute - Übersicht / Person-Suchen: Heute - Übersicht
ImpressumAGBDatenschutz
+1